Clenpiq Disease Interactions
There are 8 disease interactions with Clenpiq (citric acid/magnesium oxide/sodium picosulfate).
- Inflammatory bowel disease
- Intestinal obstruction disorders
- Renal dysfunction
- GI complications
- Renal impairment
- Arrhythmia
- Seizures
- Ulcerative colitis
Laxatives (applies to Clenpiq) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
Laxatives (applies to Clenpiq) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
Magnesium salts (applies to Clenpiq) renal dysfunction
Major Potential Hazard, High plausibility.
Magnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.
Sodium picosulfate (applies to Clenpiq) GI complications
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Perforation
Sodium picosulfate is a stimulant laxative contraindicated in patients with gastrointestinal complications, such as gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, and gastric retention.
Sodium picosulfate (applies to Clenpiq) renal impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The use of sodium picosulfate is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) as accumulation of magnesium in plasma may occur. Use caution in patients with mild to moderate renal impairment or patients taking concomitant medications that may affect renal function as these patients may be at increased risk for renal injury. It is recommended to assess baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.
Sodium picosulfate (applies to Clenpiq) arrhythmia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias, Heart Disease, Electrolyte Abnormalities
The use of sodium picosulfate may cause serious arrhythmia. Use caution when prescribing this agent in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). It is recommended to consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
Sodium picosulfate (applies to Clenpiq) seizures
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Electrolyte Abnormalities
The use of sodium picosulfate may cause generalized tonic-clonic seizures. Use caution when using this agent in patients with a history of seizures and in patients at risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality.
Sodium picosulfate (applies to Clenpiq) ulcerative colitis
Moderate Potential Hazard, Moderate plausibility.
Osmotic laxatives may produce colonic mucosal aphthous ulcerations. Sodium picosulfate should be used with caution in patients with severe active ulcerative colitis. Appropriate diagnostic studies should be performed to rule out gastrointestinal obstruction or perforation before administering this agent.
Switch to professional interaction data
Clenpiq drug interactions
There are 661 drug interactions with Clenpiq (citric acid/magnesium oxide/sodium picosulfate).
Clenpiq alcohol/food interactions
There is 1 alcohol/food interaction with Clenpiq (citric acid/magnesium oxide/sodium picosulfate).
More about Clenpiq (citric acid/magnesium oxide/sodium picosulfate)
- Clenpiq consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (305)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: laxatives
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.